Bronchiectasis Plasma

Bronchiectasis Plasma for Chronic Airway Inflammation Research

Bronchiectasis Plasma is collected from IRB-consented donors clinically diagnosed with bronchiectasis and processed within one day of collection to preserve key analytes such as cytokines, proteins and metabolites. Bronchiectasis is a chronic airway condition defined by irreversible bronchial dilatation, impaired mucus clearance, persistent neutrophil-dominated airway inflammation and recurrent or chronic bacterial infection. It arises from several different underlying causes rather than one unifying mechanism, and this human plasma supports respiratory inflammation and biomarker research.

Neutrophilic Airway Inflammation and Heterogeneous Aetiology

  • Bronchiectasis is aetiologically heterogeneous. Recognised causes include post-infectious injury, cystic fibrosis, primary and secondary immunodeficiency, primary ciliary dyskinesia, allergic bronchopulmonary aspergillosis and associated systemic inflammatory disease; a substantial proportion remains idiopathic.
  • What the phenotypes share is a self-sustaining cycle of impaired mucociliary clearance, bacterial persistence, neutrophilic airway inflammation and further structural airway damage.
  • Neutrophil recruitment and activation dominate the inflammatory profile in most patients, with neutrophil-derived proteases contributing to ongoing tissue injury; neutrophil elastase activity is among the most studied readouts.
  • Systemic inflammatory mediators including CRP, IL-6 and IL-8 rise during exacerbations, so plasma provides an accessible window on inflammatory burden and exacerbation biology.
  • Because immunodeficiency is a recognised cause, immunoglobulin quantification in plasma is directly relevant to aetiological characterisation of donor cohorts.
  • Plasma is acellular. It supports protease activity assays, immunoassay, proteomic and metabolomic profiling, but not flow cytometry or other cell-based assays.

Donor Stratification Available

  • Documented underlying aetiology: post-infectious, cystic fibrosis-related, immunodeficiency-associated, or idiopathic
  • Chronic airway infection or colonisation status where documented, including Pseudomonas aeruginosa and non-tuberculous mycobacteria
  • Exacerbation status: stable state versus acute exacerbation collections
  • Exacerbation frequency and documented disease severity
  • Treatment status: long-term macrolide therapy, inhaled or systemic antibiotics, airway clearance therapy, or immunoglobulin replacement
  • Matched healthy controls available

Product Features

  • Research Use Only (RUO)
  • Plasma collected from clinically confirmed bronchiectasis donors
  • Processed within one day of collection
  • Anticoagulant selection available on request
  • IRB-approved protocols and informed consent
  • Custom aliquot volumes available upon request

De-identified Donor Data

  • Verified bronchiectasis diagnosis, with documented aetiology where available
  • Demographic data: age, sex assigned at birth, race/ethnicity
  • Donor-reported medications, allergies, and comorbidities
  • Microbiology and exacerbation history where documented
  • Additional bronchiectasis-specific metadata available

Applications

  • Neutrophil protease and elastase activity assay development
  • Systemic inflammatory mediator and cytokine profiling
  • Exacerbation biomarker discovery and validation
  • Immunoglobulin quantification for immunodeficiency-associated cohorts
  • Plasma proteomic and metabolomic profiling of chronic airway disease
  • Host response characterisation in chronic bacterial airway infection
  • Anti-inflammatory and anti-protease therapeutic candidate research
  • Comparative studies against other chronic respiratory disease cohorts

Other Bronchiectasis Specimen Types

Compliance and Quality Assurance

  • IRB-approved and HIPAA-compliant protocols
  • Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
  • Documentation support available for regulatory review

Ordering & Customization

Bronchiectasis plasma is available in standard and custom volumes. For pricing, current availability, international orders or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse donor cohorts across our full inventory, visit our human plasma page.

Protocols & Documentation

  • Plasma Isolation

    Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

Plasma

Frequently Asked Questions

Showing 1–12 of 31 results

Are samples IRB approved?

1 Answer

YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.

YES – all our products are research use only (RUO).

Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.

Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.

Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.

Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.

YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.

Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.

YES – Unique donors can be specified and guaranteed based on your requirements.

For information about sample quality, please see: Quality and Compliance

YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.

1
×

Ask a Question

Need a custom Plasma cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information